Lingmin Yuan

Lingmin Yuan

Auto-generated profile, based on publicly available information

Lingmin Yuan

Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Molecular Cell
Verified
Journal Article
Closed access
SCShenghai Chang
Shenghai Chang
DSDapeng Sun
Dapeng Sun
HLHuanhuan Liang
Huanhuan Liang
JWJia Wang
Jia Wang
JLJun Li
Jun Li
YLYingfang Liu
Yingfang Liu

20 July 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YLYanqing Liu
Yanqing Liu
XZXiaoli Zheng
Xiaoli Zheng
QYQinqin Yu
Qinqin Yu
HWHua Wang
Hua Wang
FTFuqing Tan
Fuqing Tan
Su ZengSu Zeng
Su Zeng
Renal cell carcinoma (RCC) is known for its multidrug resistance. Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC. By analyzing OCT2 expression in collected patient tissues and commercial tissue microarray specimens, we demonstrated OCT2 repression in RCC at both transcription and protein levels. Epigenetic analysis revealed that the repressed OCT2 promoter in RCC is characterized by hypermethylated CpG islands and the absence of H3K4 methylation. Further mechanistic studies showed that DNA hypermethylation blocked MYC activation of OCT2 by disrupting its interaction with the E-Box motif, which prevented MYC from recruiting MLL1 to catalyze H3K4me3 at the OCT2 promoter and resulted in repressed OCT2 transcription. Targeting this mechanism, we designed a sequential combination therapy and demonstrated that epigenetic activation of OCT2 by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts. Our study highlights the potential of translating “omics” data into the development of targeted therapies.

1 February 2017 in Molecular Cell
Verified
Journal Article
Closed access
ZLZongyang Lv
Zongyang Lv
KRKimberly A. Rickman
Kimberly A. Rickman
LYLingmin Yuan
Lingmin Yuan
KWKatelyn Williams
Katelyn Williams
SSShanmugam Panneer Selvam
Shanmugam Panneer Selvam
SOShaun K. Olsen
Shaun K. Olsen

1 December 2011 in Biochemical Pharmacology
Verified
Journal Article
Closed access
HWHaina Wang
Haina Wang
LYLingmin Yuan
Lingmin Yuan
SZSu Zeng
Su Zeng

18 June 2013 in Cell Research
Verified
Journal Article
Closed access
FFFeng Feng
Feng Feng
LYLingmin Yuan
Lingmin Yuan
YWYao E Wang
Yao E Wang
CCChristopher Crowley
Christopher Crowley
ZLZongyang Lv
Zongyang Lv
HLHuanhuan Liang
Huanhuan Liang

1 July 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ZLZongyang Lv
Zongyang Lv
LYLingmin Yuan
Lingmin Yuan
JAJames H. Atkison
James H. Atkison
GAGrace Aldana-Masangkay
Grace Aldana-Masangkay
YCYuan Chen
Yuan Chen
SOShaun K. Olsen
Shaun K. Olsen
E1 enzymes for ubiquitin (Ub) and Ub-like modifiers (Ubls) harbor two catalytic activities that are required for Ub/Ubl activation: adenylation and thioester bond formation. Structural studies of the E1 for the Ubl small ubiquitin-like modifier (SUMO) revealed a single active site that is transformed by a conformational switch that toggles its competency for catalysis of these two distinct chemical reactions. Although the mechanisms of adenylation and thioester bond formation revealed by SUMO E1 structures are thought to be conserved in Ub E1, there is currently a lack of structural data supporting this hypothesis. Here, we present a structure of Schizosaccharomyces pombe Uba1 in which the second catalytic cysteine half-domain (SCCH domain) harboring the catalytic cysteine has undergone a 106° rotation that results in a completely different network of intramolecular interactions between the SCCH and adenylation domains and translocation of the catalytic cysteine 12 Å closer to the Ub C terminus compared with previous Uba1 structures. SCCH domain alternation is accompanied by conformational changes within the Uba1 adenylation domains that effectively disassemble the adenylation active site. Importantly, the structural and biochemical data suggest that domain alternation and remodeling of the adenylation active site are interconnected and are intrinsic structural features of Uba1 and that the overall structural basis for adenylation and thioester bond formation exhibited by SUMO E1 is indeed conserved in Ub E1. Finally, the mechanistic insights provided by the novel conformational snapshot of Uba1 presented in this study may guide efforts to develop small molecule inhibitors of this critically important enzyme that is an active target for anticancer therapeutics.